{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:08:07Z","timestamp":1782364087835,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["68633259"],"award-info":[{"award-number":["68633259"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05838-y","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T04:25:37Z","timestamp":1744950337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1065-1563","authenticated-orcid":false,"given":"George A.","family":"Karpouzas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0565-5255","authenticated-orcid":false,"given":"Sarah R.","family":"Ormseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7719-8906","authenticated-orcid":false,"given":"Piet","family":"Van Riel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2006-1436","authenticated-orcid":false,"given":"Elena","family":"Myasoedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-7406","authenticated-orcid":false,"given":"Miguel A.","family":"Gonzalez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-7798","authenticated-orcid":false,"given":"Alfonso","family":"Corrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-3863","authenticated-orcid":false,"given":"Solbritt","family":"Rantapaa-Dahlqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-2930","authenticated-orcid":false,"given":"Petros","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9357-4630","authenticated-orcid":false,"given":"Patrick","family":"Dessein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-3268","authenticated-orcid":false,"given":"Carol A.","family":"Hitchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7368-498X","authenticated-orcid":false,"given":"Virginia","family":"Pascual-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6711-2275","authenticated-orcid":false,"given":"Irazu Contreras","family":"Yanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2786-5843","authenticated-orcid":false,"given":"Iris Jazm\u00edn","family":"Colunga-Pedraza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9714-2109","authenticated-orcid":false,"given":"Dionicio Angel","family":"Galarza-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2638-9590","authenticated-orcid":false,"given":"Jose","family":"Azpiri-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-2853","authenticated-orcid":false,"given":"Anne Grete","family":"Semb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-7396","authenticated-orcid":false,"given":"Durga Prasanna","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-6176","authenticated-orcid":false,"given":"George D.","family":"Kitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2562-9174","authenticated-orcid":false,"given":"Ellen M.","family":"Hauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"5838_CR1","doi-asserted-by":"publisher","first-page":"102925","DOI":"10.1016\/j.autrev.2021.102925","volume":"21","author":"V Restivo","year":"2022","unstructured":"Restivo V, Candiloro S, Daidone M et al (2022) Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev 21:102925","journal-title":"Autoimmun Rev"},{"key":"5838_CR2","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1136\/annrheumdis-2013-203617","volume":"73","author":"GA Karpouzas","year":"2014","unstructured":"Karpouzas GA, Malpeso J, Choi T-Y et al (2014) Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis 73:1797\u20131804","journal-title":"Ann Rheum Dis"},{"key":"5838_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/art.41122","volume":"72","author":"GA Karpouzas","year":"2020","unstructured":"Karpouzas GA, Ormseth SR, Hernandez E, Budoff MJ (2020) Impact of cumulative inflammation, cardiac risk factors, and medication exposure on coronary atherosclerosis progression in rheumatoid arthritis. Arthritis Rheumatol 72:400\u2013408","journal-title":"Arthritis Rheumatol"},{"key":"5838_CR4","doi-asserted-by":"publisher","first-page":"1759720X2312010","DOI":"10.1177\/1759720X231201047","volume":"15","author":"GA Karpouzas","year":"2023","unstructured":"Karpouzas GA, Szekanecz Z, Baecklund E et al (2023) Rheumatoid arthritis disease activity and adverse events in patients receiving Tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL surveillance. Ther Adv Musculoskelet Dis 15:1759720X231201047","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5838_CR5","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.39098","volume":"67","author":"DH Solomon","year":"2015","unstructured":"Solomon DH, Reed GW, Kremer JM et al (2015) Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 67:1449\u20131455","journal-title":"Arthritis Rheumatol"},{"key":"5838_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/1744666X.2021.1899809","volume":"17","author":"GA Karpouzas","year":"2021","unstructured":"Karpouzas GA, Bui VL, Ronda N et al (2021) Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights. Expert Rev Clin Immunol 17:355\u2013374","journal-title":"Expert Rev Clin Immunol"},{"key":"5838_CR7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/art.41293","volume":"72","author":"GA Karpouzas","year":"2020","unstructured":"Karpouzas GA, Ormseth SR, Hernandez E, Budoff MJ (2020) Biologics May prevent cardiovascular events in rheumatoid arthritis by inhibiting coronary plaque formation and stabilizing high-risk lesions. Arthritis Rheumatol 72:1467\u20131475","journal-title":"Arthritis Rheumatol"},{"key":"5838_CR8","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73:1108\u20131123","journal-title":"Arthritis Rheumatol"},{"key":"5838_CR9","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/17512433.2021.1932461","volume":"14","author":"F Verhoeven","year":"2021","unstructured":"Verhoeven F, Prati C, Chouk M et al (2021) Methotrexate and cardiovascular risk in rheumatic diseases:a comprehensive review. Expert Rev Clin Pharmacol 14:1105\u20131112","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5838_CR10","doi-asserted-by":"publisher","first-page":"e24579","DOI":"10.1097\/MD.0000000000024579","volume":"100","author":"K-J Sun","year":"2021","unstructured":"Sun K-J, Liu L-L, Hu J-H et al (2021) Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: an updated meta-analysis. Med (Baltim) 100:e24579","journal-title":"Med (Baltim)"},{"key":"5838_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3899\/jrheum.200265","volume":"48","author":"G Ozen","year":"2021","unstructured":"Ozen G, Pedro S, Michaud K (2021) The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 48:648\u2013655","journal-title":"J Rheumatol"},{"key":"5838_CR12","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1136\/annrheumdis-2021-220125","volume":"80","author":"TM Johnson","year":"2021","unstructured":"Johnson TM, Sayles HR, Baker JF et al (2021) Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. Ann Rheum Dis 80:1385\u20131392","journal-title":"Ann Rheum Dis"},{"key":"5838_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/FJC.0b013e318241c385","volume":"59","author":"A Bulgarelli","year":"2012","unstructured":"Bulgarelli A, Martins Dias AA, Caramelli B, Maranh\u00e3o RC (2012) Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol 59:308\u2013314","journal-title":"J Cardiovasc Pharmacol"},{"key":"5838_CR14","doi-asserted-by":"publisher","first-page":"1601286","DOI":"10.1002\/adhm.201601286","volume":"6","author":"C Stigliano","year":"2017","unstructured":"Stigliano C, Ramirez MR, Singh JV et al (2017) Methotraxate-loaded hybrid nanoconstructs target vascular lesions and inhibit atherosclerosis progression in ApoE-\/- mice. Adv Healthc Mater 6:1601286","journal-title":"Adv Healthc Mater"},{"key":"5838_CR15","doi-asserted-by":"publisher","first-page":"37943","DOI":"10.1021\/acsami.0c12202","volume":"12","author":"V Di Francesco","year":"2020","unstructured":"Di Francesco V, Gurgone D, Palomba R et al (2020) Modulating lipoprotein transcellular transport and atherosclerotic plaque formation in ApoE-\/- mice via nanoformulated lipid-methotrexate conjugates. ACS Appl Mater Interfaces 12:37943\u201337956","journal-title":"ACS Appl Mater Interfaces"},{"key":"5838_CR16","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1002\/art.24040","volume":"58","author":"AB Reiss","year":"2008","unstructured":"Reiss AB, Carsons SE, Anwar K et al (2008) Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages. Arthritis Rheum 58:3675\u20133683","journal-title":"Arthritis Rheum"},{"key":"5838_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/ard.60.8.729","volume":"60","author":"M Cutolo","year":"2001","unstructured":"Cutolo M, Sulli A, Pizzorni C et al (2001) Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 60:729\u2013735","journal-title":"Ann Rheum Dis"},{"key":"5838_CR18","doi-asserted-by":"publisher","first-page":"503028","DOI":"10.1155\/2011\/503028","volume":"2011","author":"E Coomes","year":"2011","unstructured":"Coomes E, Chan ESL, Reiss AB (2011) Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol 2011:503028","journal-title":"Cholesterol"},{"key":"5838_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jcmg.2010.04.011","volume":"3","author":"K Inoue","year":"2010","unstructured":"Inoue K, Motoyama S, Sarai M et al (2010) Serial coronary CT angiography-verified changes in plaque characteristics as an end point: evaluation of effect of Statin intervention. JACC Cardiovasc Imaging 3:691\u2013698","journal-title":"JACC Cardiovasc Imaging"},{"key":"5838_CR20","doi-asserted-by":"publisher","first-page":"e58064","DOI":"10.7554\/eLife.58064","volume":"10","author":"D Yang","year":"2021","unstructured":"Yang D, Haemmig S, Zhou H et al (2021) Methotrexate attenuates vascular inflammation through an adenosine-microRNA-dependent pathway. Elife 10:e58064","journal-title":"Elife"},{"key":"5838_CR21","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1002\/art.27629","volume":"62","author":"JT Giles","year":"2010","unstructured":"Giles JT, Allison M, Blumenthal RS et al (2010) Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 62:3173\u20133182","journal-title":"Arthritis Rheum"},{"key":"5838_CR22","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3899\/jrheum.090838","volume":"37","author":"J Drouin","year":"2010","unstructured":"Drouin J, Haraoui B, 3e Initiative Group (2010) Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy. J Rheumatol 37:1405\u20131410","journal-title":"J Rheumatol"},{"key":"5838_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/ard.2010.139212","volume":"70","author":"S Saevarsdottir","year":"2011","unstructured":"Saevarsdottir S, Wallin H, Seddighzadeh M et al (2011) Predictors of response to methotrexate in early DMARD Naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 70:469\u2013475","journal-title":"Ann Rheum Dis"},{"key":"5838_CR24","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Choi","year":"2002","unstructured":"Choi HK, Hern\u00e1n MA, Seeger JD et al (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173\u20131177","journal-title":"Lancet"},{"key":"5838_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7","volume":"43","author":"D Krause","year":"2000","unstructured":"Krause D, Schleusser B, Herborn G, Rau R (2000) Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43:14\u201321","journal-title":"Arthritis Rheum"},{"key":"5838_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1749-6632.2002.tb04220.x","volume":"966","author":"M Cutolo","year":"2002","unstructured":"Cutolo M, Sulli A, Craviotto C et al (2002) Antiproliferative-antiinflammatory effects of methotrexate and sex hormones on cultured differentiating myeloid monocytic cells (THP-1). Ann N Y Acad Sci 966:232\u2013237","journal-title":"Ann N Y Acad Sci"},{"key":"5838_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3233\/CH-211343","volume":"81","author":"L Han","year":"2022","unstructured":"Han L, Guo M, Wang B et al (2022) Sex-differential downregulation of methotrexate on plasma viscosity and whole blood viscosity in psoriasis. Clin Hemorheol Microcirc 81:305\u2013314","journal-title":"Clin Hemorheol Microcirc"},{"key":"5838_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-021-02715-4","volume":"24","author":"B Wang","year":"2022","unstructured":"Wang B, Deng H, Hu Y et al (2022) The difference of lipid profiles between psoriasis with arthritis and psoriasis without arthritis and sex-specific downregulation of methotrexate on the Apolipoprotein B\/apolipoprotein A-1 ratio. Arthritis Res Ther 24:17","journal-title":"Arthritis Res Ther"},{"key":"5838_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","volume":"77","author":"CS Crowson","year":"2018","unstructured":"Crowson CS, Rollefstad S, Ikdahl E et al (2018) Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 77:48\u201354","journal-title":"Ann Rheum Dis"},{"key":"5838_CR30","doi-asserted-by":"publisher","first-page":"e0174656","DOI":"10.1371\/journal.pone.0174656","volume":"12","author":"CS Crowson","year":"2017","unstructured":"Crowson CS, Rollefstad S, Kitas GD et al (2017) Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. PLoS ONE 12:e0174656","journal-title":"PLoS ONE"},{"key":"5838_CR31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T et al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74:480\u2013489","journal-title":"Ann Rheum Dis"},{"key":"5838_CR32","first-page":"2","volume":"16","author":"R De Vecchis","year":"2016","unstructured":"De Vecchis R, Baldi C, Palmisani L (2016) Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data. Anatol J Cardiol 16:2\u20139","journal-title":"Anatol J Cardiol"},{"key":"5838_CR33","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","volume":"108","author":"R Micha","year":"2011","unstructured":"Micha R, Imamura F, von Ballmoos MW et al (2011) Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108:1362\u20131370","journal-title":"Am J Cardiol"},{"key":"5838_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/rheumatology\/kep366","volume":"49","author":"SL Westlake","year":"2010","unstructured":"Westlake SL, Colebatch AN, Baird J et al (2010) The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 49:295\u2013307","journal-title":"Rheumatology"},{"key":"5838_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","volume":"52","author":"S Prodanowich","year":"2005","unstructured":"Prodanowich S, Ma F, Taylor JR et al (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262\u2013267","journal-title":"J Am Acad Dermatol"},{"key":"5838_CR36","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1002\/art.22255","volume":"54","author":"DH Solomon","year":"2006","unstructured":"Solomon DH, Avorn J, Katz JN et al (2006) Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 54:3790\u20133798","journal-title":"Arthritis Rheum"},{"key":"5838_CR37","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#","volume":"44","author":"ID del Rinc\u00f3n","year":"2001","unstructured":"del Rinc\u00f3n ID, Williams K, Stern MP et al (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737\u20132745","journal-title":"Arthritis Rheum"},{"key":"5838_CR38","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1194\/jlr.M700510-JLR200","volume":"49","author":"G Catalano","year":"2008","unstructured":"Catalano G, Duchene E, Julia Z et al (2008) Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects. J Lipid Res 49:635\u2013643","journal-title":"J Lipid Res"},{"key":"5838_CR39","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/art.41693","volume":"73","author":"GA Karpouzas","year":"2021","unstructured":"Karpouzas GA, Rezaeian P, Ormseth SR et al (2021) Epicardial adipose tissue volume as a marker of subclinical coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheumatol 73:1412\u20131420","journal-title":"Arthritis Rheumatol"},{"key":"5838_CR40","doi-asserted-by":"publisher","first-page":"R110","DOI":"10.1186\/ar2765","volume":"11","author":"TE Toms","year":"2009","unstructured":"Toms TE, Panoulas VF, John H et al (2009) Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 11:R110","journal-title":"Arthritis Res Ther"},{"key":"5838_CR41","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/pharmaceutics15061661","volume":"15","author":"FC Ceballos","year":"2023","unstructured":"Ceballos FC, Chamizo-Carmona E, Mata-Mart\u00edn C et al (2023) Pharmacogenetic sex-specific effects of methotrexate response in patients with rheumatoid arthritis. Pharmaceutics 15:1661","journal-title":"Pharmaceutics"},{"key":"5838_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jsbmb.2009.04.008","volume":"116","author":"RM Badeau","year":"2009","unstructured":"Badeau RM, Metso J, W\u00e4h\u00e4l\u00e4 K et al (2009) Human macrophage cholesterol efflux potential is enhanced by HDL-associated 17beta-estradiol fatty acyl esters. J Steroid Biochem Mol Biol 116:44\u201349","journal-title":"J Steroid Biochem Mol Biol"},{"key":"5838_CR43","doi-asserted-by":"publisher","first-page":"103029","DOI":"10.1016\/j.jaut.2023.103029","volume":"136","author":"GA Karpouzas","year":"2023","unstructured":"Karpouzas GA, Papotti B, Ormseth SR et al (2023) ATP-binding cassette G1 membrane transporter-mediated cholesterol efflux capacity influences coronary atherosclerosis and cardiovascular risk in rheumatoid arthritis. J Autoimmun 136:103029","journal-title":"J Autoimmun"},{"key":"5838_CR44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jsbmb.2004.12.024","volume":"93","author":"Y Nakamura","year":"2005","unstructured":"Nakamura Y, Suzuki T, Sasano H (2005) Estrogen actions and in situ synthesis in human vascular smooth muscle cells and their correlation with atherosclerosis. J Steroid Biochem Mol Biol 93:263\u2013268","journal-title":"J Steroid Biochem Mol Biol"},{"key":"5838_CR45","doi-asserted-by":"crossref","unstructured":"Karpouzas G, Papotti B, Ormseth S et al (2024) Age, seropositivity and inflammation determine risk versus benefit of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis [abstract]. Arthritis Rheumatol 76(Suppl 9)","DOI":"10.1136\/annrheumdis-2024-eular.3719"},{"key":"5838_CR46","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/aje\/kwv225","volume":"182","author":"J Vandenbroucke","year":"2015","unstructured":"Vandenbroucke J, Pearce N (2015) Point: incident exposures, prevalent exposures, and causal inference: does limiting studies to persons who are followed from first exposure onward damage epidemiology? Am J Epidemiol 182:826\u2013833","journal-title":"Am J Epidemiol"},{"key":"5838_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/CLEP.S178723","volume":"11","author":"M Sharma","year":"2018","unstructured":"Sharma M, Nazareth I, Petersen I (2018) Observational studies of treatment effectiveness: worthwhile or worthless? Clin Epidemiol 11:35\u201342","journal-title":"Clin Epidemiol"},{"key":"5838_CR48","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1365-2796.2010.02260.x","volume":"268","author":"ME Holmqvist","year":"2010","unstructured":"Holmqvist ME, Wedr\u00e9n S, Jacobsson LTH et al (2010) Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 268:578\u2013585","journal-title":"J Intern Med"},{"key":"5838_CR49","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1002\/art.24855","volume":"60","author":"ME Holmqvist","year":"2009","unstructured":"Holmqvist ME, Wedr\u00e9n S, Jacobsson LTH et al (2009) No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 60:2861\u20132869","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05838-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05838-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05838-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T13:04:03Z","timestamp":1748005443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05838-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["5838"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05838-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review boards of all participating centers and performed in accordance with the 1964 Declaration of Helsinki and its later amendments. These included the Mayo Clinic and Olmsted Medical Center Institutional Review Boards, CMO Arnhem Nijmegen, Dudley Local Research Ethics Committee, Office of the Oslo University Hospital\u2019s Privacy and Data Protection Officer, Ethics Committee at the University Hospital of Ume\u00e5, John F Wolfe MD. Human Subjects Committee at Harbor-UCLA (project number of 13564-01, approval date 8\/26\/2009), Laiko Hospital Institutional Review Board (Athens, Greece), Human Research Ethics Committee (Medical) from the University of the Witwatersrand in Johannesburg, South Africa, University of Manitoba Health Research Ethics Board and the Manitoba Health Information Privacy Committee, Ethics Committee of Cantabria for Hospital Universitario de Valdecilla in Santander (Spain), Comites de \u00c9tica e Investigaci\u00f3n del Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, and Arthritis Center Twente Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no conflict of interest to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"106"}}